文献速递甲状腺疾病

DNA高甲基化抑制甲状腺过氧化物酶表达,或为甲状腺癌诊断标志物

DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer.
PubMed 文献 · Thyroid · 2026-03-04

本研究探讨甲状腺过氧化物酶(TPO)在甲状腺癌中沉默的表观遗传机制及其诊断价值。利用TCGA甲状腺癌数据与临床组织样本分析TPO甲基化与表达,并在细胞系中以去甲基化药物处理验证。发现DNA高甲基化通过招募MBD2抑制TPO转录,基于焦磷酸测序的TPO甲基化定量可区分恶性与良性结节。

要点

  • TPO在甲状腺癌中表达显著下调,与TPO差异甲基化区(DMR)甲基化水平呈强负相关。
  • 去甲基化药物处理可降低TPO DMR甲基化并恢复TPO表达,机制涉及MBD2招募。
  • TPO DMR内两个CpG位点诊断甲状腺癌的AUC分别为0.927和0.916。

核心结论

  • DNA高甲基化通过招募MBD2抑制甲状腺癌中TPO转录。
  • 焦磷酸测序定量TPO甲基化有望区分恶性癌与良性甲状腺结节。
  • 作者指出仍需进一步研究确认其临床诊断效用。

研究设计与样本

  • 基于TCGA甲状腺癌数据集用Infinium HumanMethylation450芯片与转录组数据分析TPO甲基化与表达。
  • 临床组织样本以亚硫酸氢盐测序PCR和qPCR验证。
  • 甲状腺癌细胞系MDA-T41、KTC-1、CAL62、TTA1经去甲基化药物地西他滨处理并分析甲基化与mRNA表达。
  • 以DNA pull-down结合LC-MS/MS筛选调控蛋白,并经染色质免疫沉淀、荧光素酶报告基因与qPCR验证。
  • 设计焦磷酸测序法量化TPO甲基化水平。

主要发现

  • TPO在甲状腺癌中表达明显下调,与TPO DMR甲基化水平呈强负相关。
  • 地西他滨处理使甲状腺癌细胞TPO DMR甲基化显著降低、TPO表达升高。
  • 机制分析显示DNA高甲基化通过招募MBD2抑制TPO表达。
  • 恶性与良性甲状腺结节(BTN)之间TPO甲基化水平存在显著差异。
  • TPO DMR内两个CpG位点诊断AUC分别为0.927(95%CI:0.864-0.989)和0.916(95%CI:0.846-0.987)。

关键数值与推荐

  • TPO DMR两个CpG位点诊断效能AUC为0.927(95%CI:0.864-0.989)与0.916(95%CI:0.846-0.987)。

临床怎么用

  • 提示TPO甲基化焦磷酸测序可作为鉴别甲状腺恶性与良性结节的候选分子诊断方法。
  • 临床应用于诊断前需进一步研究确认其诊断效用。

局限性

  • 作者结论指出需进一步研究以确认这些发现的临床诊断效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decreased expression of thyroid peroxidase (TPO) is frequently observed in thyroid cancer, but the underlying regulatory mechanism remains largely unknown. This study aimed to elucidate the epigenetic basis of TPO silencing and assess its potential value for the diagnosis of thyroid cancer. METHODS: DNA methylation and expression levels of TPO were analyzed using the Infinium HumanMethylation450 array and transcriptome data from The Cancer Genome Atlas thyroid cancer dataset and validated in clinical tissue samples by bisulfite sequencing polymerase chain reaction (PCR) and quantitative PCR (qPCR). Thyroid cancer cell lines MDA-T41, KTC-1, CAL62, and TTA1 were treated with the demethylating drug decitabine and subjected to DNA methylation and mRNA expression analyses. Potential regulatory proteins were identified through DNA pull-down coupled with LC-MS/MS and validated by chromatin immunoprecipitation, luciferase reporter assay, and qPCR. A pyrosequencing assay was designed to quantify the methylation level of TPO. RESULTS: TPO expression was markedly downregulated in thyroid cancer and showed a strong inverse correlation with DNA methylation level at TPO differentially methylated region (DMR). Treatment of thyroid cancer cells with decitabine induced significantly decreased methylation level of TPO DMR and increased expression of TPO. Mechanistic analyses demonstrated that DNA hypermethylation suppressed TPO expression by recruiting methyl-CpG binding domain protein 2 (MBD2). Moreover, a pyrosequencing-based method for quantifying TPO methylation level was developed, and a remarkable difference between malignant and benign thyroid nodules (BTNs) was observed. Two CpG sites within TPO DMR achieved diagnostic performance with areas under the receiver operating characteristic curves of 0.927 (95% confidence interval [CI]: 0.864-0.989) and 0.916 (95% CI: 0.846-0.987), respectively. CONCLUSIONS: DNA hypermethylation suppresses TPO transcription by recruiting MBD2 in thyroid cancer. Quantitative assessment of TPO methylation by pyrosequencing offers a promising molecular diagnostic approach to distinguish malignant cancer from BTN. Further studies are warranted to ascertain the clinical diagnostic utility of these findings.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Zhu L, Jiang K, Huang J, et al. DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May Be a Promising Diagnostic Marker for Thyroid Cancer. Thyroid. 2026. PMID: 41778292. doi:10.1177/10507256261427034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。